Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 14;15(11):2254.
doi: 10.3390/v15112254.

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

Ralph A Tripp  1 , David E Martin  2
Affiliations

Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19

Ralph A Tripp et al. Viruses. .

Abstract

In the early stages of drug discovery, researchers develop assays that are compatible with high throughput screening (HTS) and structure activity relationship (SAR) measurements. These assays are designed to evaluate the effectiveness of new and known molecular entities, typically targeting specific features within the virus. Drugs that inhibit virus replication by inhibiting a host gene or pathway are often missed because the goal is to identify active antiviral agents against known viral targets. Screening efforts should be sufficiently robust to identify all potential targets regardless of the antiviral mechanism to avoid misleading conclusions.

Keywords: direct-acting antiviral (DDA); drug discovery assays; host-directed antiviral (HDA); probenecid; virus.

PubMed Disclaimer

Conflict of interest statement

R.A.T. declares no conflict of interest. D.E.M. is an employee of TrippBio.

Similar articles

See all similar articles

Cited by

References

    1. Kiriiri G.K., Njogu P.M., Mwangi A.N. Exploring different approaches to improve the success of drug discovery and development projects: A review. Future J. Pharm. Sci. 2020;6:27. doi: 10.1186/s43094-020-00047-9. - DOI
    1. Sun D., Gao W., Hu H., Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B. 2022;12:3049–3062. doi: 10.1016/j.apsb.2022.02.002. - DOI - PMC - PubMed
    1. Seyhan A.A. Lost in translation: The valley of death across preclinical and clinical divide–identification of problems and overcoming obstacles. Transl. Med. Commun. 2019;4:18. doi: 10.1186/s41231-019-0050-7. - DOI
    1. Low J.G., Gatsinga R., Vasudevan S.G., Sampath A. Dengue Antiviral Development: A Continuing Journey. Adv. Exp. Med. Biol. 2018;1062:319–332. - PubMed
    1. Kaufmann S.H.E., Dorhoi A., Hotchkiss R.S., Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug. Discov. 2018;17:35–56. doi: 10.1038/nrd.2017.162. - DOI - PMC - PubMed